Advanced Bladder Cancer VL

Molecular Subtyping and Neoadjuvant Chemotherapy in Bladder Cancer - Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen discuss a publication entitled, “Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.” This study is investigating how molecular subtypes impact pathological response and survival in patients receiving preoperative cisplatin-based chemotherapy. This study shows that tumor classification by gene expression profiling and...

Pembrolizumab Alone or Combined With Chemotherapy vs Chemotherapy As First-Line Therapy for Advanced Urothelial Carcinoma in the KEYNOTE-361 Trial Journal Club – Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen discuss a Lancet Oncology publication on the KEYNOTE-361 trial, pembrolizumab alone, or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma: A randomized open-label phase three trial. The authors of this trial assessed outcomes with first-line pembrolizumab alone or combined with chemotherapy versus chemothe...

CheckMate 274 Trial of Adjuvant Nivolumab vs Placebo in Patients Who Underwent Radical Surgery for High-Risk Muscle-Invasive Urothelial Carcinoma, Journal Club - Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen discuss the CheckMate 274 publication, “Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.” The role of adjuvant treatment in high-risk muscle-invasive urothelial carcinoma after radical surgery is not clear. The authors of this publication assigned patients with muscle-invasive urothelial carcinoma who had undergone radical surgery t...

The Role of Risk-Stratified Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer Who Are Undergoing Radical Cystectomy - Arlene O. Siefker-Radtke and Shilpa Gupta

Details
In this conversation, Arlene Siefker-Radtke and Shilpa Gupta join Patrick Hensley to discuss the role of risk-stratified neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer who are undergoing radical cystectomy. Drs. Siefker-Radtke and Gupta explain how systemic chemotherapy can be very challenging for bladder cancer patients due to the long-term side effects it can cause, alo...

ATLANTIS Trial Explores Precision Medicine in Urothelial Carcinoma - Robert Jones

Details
Alicia Morgans speaks with Robert Jones about the ATLANTIS Trial, focusing on an embedded randomization that studied the efficacy of Cabozantinib in urothelial carcinoma patients post-chemotherapy. Dr. Jones explains that the ATLANTIS platform aims to explore precision medicine in urothelial cancer and includes an "all-comers" arm to ensure broader patient participation. Unfortunately, the study f...

Overall Response Rate After Immune-Checkpoint Inhibitor Initiation and Post-ICI PFS in Patients With Advanced Urothelial Carcinoma - Dimitrios Makrakis

Details
Petros Grivas is joined by Dimitrios Makrakis to discuss his multi-institutional retrospective cohort study of patients with advanced urothelial carcinoma (UC) who received platinum-based chemotherapy in the first line, followed by second-line immune checkpoint inhibitor (ICI). In this study, the timely question of how the duration of response to immune checkpoint inhibitor may be interpreted as p...

Outcomes Between Patients With and Without Prior Intravesical BCG, Who Received Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma - Rafee Talukder & Petros Grivas

Details
In this conversation with Alicia Morgans, Rafee Talukder and Petros Grivas share data that investigates comparing the outcomes in patients who received prior intravesical BCG, and those patients who progressed and then required immune checkpoint inhibitors, to see if prior BCG therapy had an effect on the response on immune checkpoint inhibitors. Their hypothesis was, that patients who received BC...

Navigating the Complex Landscape of Adjuvant Trials in Urothelial Carcinoma - Robert Dreicer

Details
Sam Chang and Robert Dreicer delve into the evolving landscape of adjuvant trials for urothelial carcinoma. Dr. Dreicer discusses three pivotal studies: IMvigor010, CheckMate 274, and AMBASSADOR, each exploring different drugs like atezolizumab, nivolumab, and pembrolizumab in high-risk patient populations. While IMvigor010 showed negative results, CheckMate 274 demonstrated a disease-free surviva...

The Role of ctDNA in Metastatic Urothelial Cancer - Alexander Wyatt

Details
Ashish Kamat hosts Alexander Wyatt to discuss the role of circulating tumor DNA (ctDNA) in the clinical management of urothelial carcinoma, especially in metastatic cases. Dr. Wyatt highlights ctDNA's utility in cancer screening, residual disease detection, and therapy monitoring. Data indicates that higher levels of ctDNA often correlate with worse disease prognosis. The conversation also explore...

Antibody-Drug Conjugates in Advanced Urothelial Cancer: Clinical Perspective - Scott Tagawa

Details
Scott Tagawa joins Sam Chang to highlight the key topics of his discussion at the American Society for Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2022. Dr. Tagawa provided a clinical perspective on antibody-drug conjugates in the treatment of urothelial carcinoma. Biographies: Scott T. Tagawa, MD, Associate Professor of Clinical Medicine, Clinical Urology, Medical Director, Genitourin...